Search Results 401-410 of 38054 for Two-phase

  1. Oncology (Medical) - Clinical trials

    This is a phase 1b/2 study of the safety and efficacy of MLN0128 in combination with exemestane or fulvestrant therapy in women with estrogen receptor positive/ ...

  2. Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma - Mayo Clinic

    About this study. This open-label, randomized, 2-arm, multicenter, phase 3 study has the primary objective of comparing the modified progression-free ...

  3. Weekly dose of erlotinib shows decreased duodenal polyp burden and side effects for patients with FAP - Mayo Clinic

    Results of the multicenter, single-arm, phase 2 trial were published to Gut online in May 2022. FAP is a genetic cancer syndrome. Therefore patients with ...

  4. HER2-Positive Breast Cancer Clinical Trials - Mayo Clinic Research

    ... 2 (HER2)-positive stage I-III breast cancer. HER2 is a protein found on the ... In the phase II part, to evaluate the preliminary antitumor activity of two ...

  5. A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants - Mayo Clinic

    ... phase followed by an expansion phase. The dose-escalation phase is designed to determine the recommended phase 2 dose (RP2D) for idasanutlin in combination ...

  6. Lymphoma Clinical Trials - Mayo Clinic Research

    The dose-escalation phase is designed to determine the recommended phase 2 dose (RP2D) for idasanutlin in combination with obinutuzumab for FL and in ...

  7. Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer - Mayo Clinic

    About this study. This is a multicenter, open-label, Phase 1, dose escalation trial to evaluate the safety, tolerability, and recommended Phase 2 dose ...

  8. A Study to Evaluate the Combination of Margetuximab, Retifanlimab, MGD013, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer - Mayo Clinic

    A Study to Evaluate the Combination of Margetuximab, Retifanlimab, MGD013, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer · Overview · Participation ...

  9. A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma - Mayo Clinic

    The study consists of two parts: Dose escalation (Part A): In this part, up ... phase 2 dose (RP2D) of SAR446523. Participation eligibility. Participant ...

  10. Home Care Treatment With Oral Chemotherapy For Recurrent Or Metastatic Oral Cavity Cancer - Mayo Clinic

    Study phase. 2. During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase ...